
    the trial was prematurely terminated on 01april2014 due to safety concerns.
  
['migraine']
['pf-05180999', 'placebo', '120 mg mr pf-05180999', '360 mg mr pf-05180999', '10 mg cetirizine', 'placebo']

        Inclusion Criteria:

          -  Healthy male subjects between the ages of 18 and 55 years

          -  No history of clinically-relevant atopic or dermatological disease

          -  Positive reaction to intradermal injection of histamine

        Exclusion Criteria:

          -  Subjects with screening laboratory test results that deviate from the upper and/or
             lower limits of the reference or acceptable range. The exception is that all liver
             function tests must not exceed the upper limit of normal.

          -  Subjects with evidence of, or history of, hepatic disorder, including acute or chronic
             hepatitis B or hepatitis C

          -  Intolerance to intradermal histamine injection.

          -  Subjects with dark skin (Part B only).
      